Role of RSUME in inflammation and cancer (Q38571655)

4 September 2017

Role of RSUME in inflammation and cancer (English)

1 reference

4 September 2017

Valeria G Antico Arciuch

1

1 reference

4 September 2017

Lucas Tedesco

2

1 reference

4 September 2017

Mariana Fuertes

3

1 reference

4 September 2017

Eduardo Arzt

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

19 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

589

1 reference

4 September 2017

22

1 reference

4 September 2017

3330-3335

1 reference

RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of pituitary lactosomatotrophic GH3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

In silico structural and functional characterization of the RSUME splice variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

RSUME enhances glucocorticoid receptor SUMOylation and transcriptional activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

RSUME is implicated in HIF-1-induced VEGF-A production in pituitary tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

SUMO: a history of modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Protein modification by SUMO

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

The ubiquitin-proteasome proteolytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Origin and function of ubiquitin-like proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

A proteomic study of SUMO-2 target proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

SUMO--nonclassical ubiquitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

SUMO: ligases, isopeptidases and nuclear pores

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

RWD Domain as an E2 (Ubc9)-Interaction Module

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Hypoxia-inducible factors: central regulators of the tumor phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

HIF-1 mediates the Warburg effect in clear cell renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Concurrent gene signatures for han chinese breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Pathophysiological role of the cytokine network in the anterior pituitary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

The pathogenesis of pituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

The prevalence of pituitary adenomas: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Angiogenesis in endocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Platelet-derived growth factor in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Molecular markers of glioma: an update on recent progress and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

von Hippel-Lindau disease: a clinical and scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Central nervous system capillary haemangioblastoma: the pathologist's viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Proline hydroxylation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Molecular understanding of cytokine-steroid hormone dialogue: implications for human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Glucocorticoids in T cell development and function*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Glucocorticoids in the regulation of transcription factors that control cytokine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Functional interactions between Stat5 and the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

Potentiation of glucocorticoid receptor transcriptional activity by sumoylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2015.07.048

10.1016/J.FEBSLET.2015.07.048

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference